Adding PD-(L)1 inhibitors to chemotherapy improved outcomes, but PD-(L)1 inhibitors alone were no more effective than chemotherapy alone in patients with gastric, gastroesophageal junction, and ...

Treatment with ¹⁷⁷Lu-PSMA-617 appears more effective than changing ARPIs for patients with mCRPC whose disease progressed on a prior ARPI.

(HealthDay News) — Axatilimab produces responses in patients with recurrent or refractory graft-vs-host disease (GVHD), according to a study published in The New England Journal of Medicine.

Americans have the worst health care among the world’s wealthy nations, according to a report from health care think-tank The Commonwealth Fund. The report showed that people in the United States die ...

SBRT and hypofractionated CRT produced similar outcomes in patients with inoperable stage I NSCLC in a phase 3 trial.

A large study suggests that pediatric cancer patients are more likely to die in the hospital than at home. The data showed that 52% of patients died in the hospital, and 40% died at home. These ...

The FDA has approved Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone for transplant-ineligible, newly diagnosed multiple myeloma.

A novel CAR T-cell therapy, GCC19CART, has demonstrated activity in patients with heavily pretreated, metastatic colorectal cancer.

Retifanlimab improved upon standard chemotherapy in patients with locally recurrent or metastatic anal cancer in a phase 3 ...

The FDA has approved Rybrevant (amivantamab) in combination with chemotherapy to treat advanced, EGFR-mutant NSCLC that progressed on or after treatment with an EGFR TKI.

Adding radium-223 to treatment with enzalutamide and a bone-protecting agent improved rPFS and OS in patients with mCRPC and ...

The US Food and Drug Administration (FDA) has approved a 420 mg dosage strength of Hercessi (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab). Hercessi, a HER2/neu receptor antagonist, is ...